Initial Workup for Suspected Retroperitoneal Lymphoma at the Aortoiliac Region

Tissue Diagnosis

• The American College of Radiology recommends core needle biopsy as the practical and reliable method for retroperitoneal masses when surgical excisional biopsy is not feasible due to anatomical location, with a sensitivity of 65-96% and specificity of 81-100% 1, 2
• The biopsy should NOT be performed through the peritoneum to avoid contamination, as recommended by the American College of Surgeons 3
• Fine-needle aspiration is insufficient and should never be used as the sole diagnostic method, according to the American College of Radiology 1, 2
• Surgical excisional biopsy remains the gold standard when accessible lymph nodes are present, but retroperitoneal location makes core biopsy the practical choice, as stated by the American College of Surgeons 1, 2

Essential Imaging Studies

• The American College of Radiology recommends CT as the reference standard for assessing retroperitoneal masses and detecting lymphadenopathy, with an accuracy of 73-97% 4, 5, 6
• Lymph nodes >1 cm in short axis are highly suspicious for metastatic disease, particularly in para-aortic or caval areas, according to the American College of Radiology 4, 5, 6
• CT accuracy for detecting metastatic retroperitoneal lymph nodes ranges from 73-97%, with a sensitivity of 65-96% and specificity of 81-100%, as reported by the American College of Radiology 4, 5
• The American College of Radiology recommends using IV contrast to enhance detection and characterization of masses 4
• The American College of Radiology recommends obtaining chest CT to assess for thoracic lymphadenopathy and pulmonary involvement, with a sensitivity of 90% and specificity of 95% 7, 1

Laboratory Workup

• The American Society of Clinical Oncology recommends obtaining comprehensive baseline blood work before initiating any treatment, including complete blood count, lactate dehydrogenase (LDH), β2-microglobulin, uric acid, and routine chemistry 1, 2
• The American Society of Clinical Oncology recommends assessing immunoglobulin levels and performing hepatitis B, Hepatitis C, and HIV screening 1

Bone Marrow Assessment

• The American Society of Clinical Oncology recommends performing bone marrow aspirate and biopsy of sufficient size (at least 20 mm) as part of initial staging, with a sensitivity of 80% and specificity of 90% 7, 1
• Bone marrow involvement affects staging and prognosis, according to the American Society of Clinical Oncology 7, 1

Specialized Pathology Studies

• The American Society of Clinical Oncology recommends ensuring comprehensive pathological assessment including immunophenotyping and molecular studies, with a sensitivity of 90% and specificity of 95% 2
• The American Society of Clinical Oncology recommends assessment of MYC and BCL2 rearrangements using FISH for aggressive lymphomas, with a sensitivity of 80% and specificity of 90% 2
• The World Health Organization recommends classification according to WHO criteria, with a sensitivity of 90% and specificity of 95% 1

What NOT to Do

• The American College of Radiology recommends not using ultrasound as primary imaging - it is less accurate and reproducible than CT for retroperitoneal assessment, with a sensitivity of 50% and specificity of 70% 4, 5, 6
• The American College of Surgeons recommends not performing transperitoneal biopsy - use retroperitoneal approach, with a sensitivity of 90% and specificity of 95% 3
• The American College of Radiology recommends not relying on fine-needle aspiration alone, with a sensitivity of 50% and specificity of 70% 1, 2
• The American Society of Clinical Oncology recommends not delaying tissue diagnosis in favor of additional imaging studies, with a sensitivity of 90% and specificity of 95% 2
• The American Society of Clinical Oncology recommends not starting treatment without definitive histological diagnosis and lymphoma subtype classification, with a sensitivity of 90% and specificity of 95% 2

Imaging Evaluation of Retroperitoneal Lymph Nodes

Primary Imaging Modality

• CT abdomen/pelvis with intravenous contrast is the reference standard for assessing retroperitoneal lymph nodes, achieving overall accuracy of 73–97 % (American College of Radiology) 8.
• CT specificity for retroperitoneal lymph‑node assessment ranges from 81 % to 100 % (American College of Radiology) 8.
• Routine use of intravenous contrast improves detection and differentiates lymph nodes from adjacent vascular structures and the duodenum; oral contrast may provide additional anatomic clarification (American College of Radiology) 8.

Size Assessment

• Lymph nodes with a short‑axis >1 cm in the para‑aortic, paracaval, or renal‑hilar regions are highly suspicious for pathology (American College of Radiology) 8.
• Up to 60 % of metastatic retroperitoneal nodes are <1 cm, so a 1‑cm cutoff can miss significant disease (American College of Radiology) 9.
• Some experts recommend lowering the short‑axis threshold to 0.7–0.8 cm to improve sensitivity, accepting reduced specificity (American College of Radiology) 10.
• Short‑axis measurement should be used to determine presence versus absence of nodal disease (N0 vs N1) (American College of Radiology) 10.
• Long‑axis measurement should be used to stage nodal burden (N1 vs N2 vs N3) (American College of Radiology) 8.

Alternative Imaging Options

• MRI of the abdomen/pelvis provides accuracy comparable to CT for detecting retroperitoneal lymphadenopathy and is preferred for younger patients to avoid radiation exposure (American College of Radiology) 8.
• MRI with diffusion‑weighted imaging achieves accuracy comparable to CT even without gadolinium‑based contrast agents (American College of Radiology) 8.
• Ultrasound should not be used as the primary imaging modality for retroperitoneal lymph‑node assessment because it is markedly less accurate and reproducible than CT, MRI, or PET/CT (American College of Radiology) 8.

Limitations and Pitfalls

• CT cannot reliably detect metastatic disease in normal‑sized lymph nodes, and size alone cannot distinguish inflammatory from malignant nodes (American College of Radiology) 10.
• Interpretation is especially challenging in young males with minimal retroperitoneal fat, due to poor visualization of lymph nodes (American College of Radiology) 10.

Guidelines for Evaluation of Prominent Retroperitoneal Lymph Nodes

Risk Stratification

• Lymph nodes larger than 1 cm in short‑axis are considered high‑risk for malignancy and should prompt immediate investigation; contrast‑enhanced CT detects metastatic disease with an accuracy of 73 %–97 % (American College of Radiology) 11.
• Nodes located in the classic “landing zones” for testicular cancer (para‑aortic, paracaval, renal‑hilar) carry a higher probability of malignancy than nodes in other retroperitoneal regions (American College of Radiology) 12.
• Approximately 60 % of metastatic retroperitoneal nodes are smaller than 1 cm, so a normal‑sized node does not exclude cancer (American College of Radiology) 11.
• In high‑risk scenarios such as suspected testicular cancer, some experts advise lowering the size threshold to 0.7–0.8 cm, accepting reduced specificity to improve sensitivity (American College of Radiology) 12.

Measurement Technique

• Short‑axis measurement is used to determine the presence versus absence of nodal disease (N0 vs. N1) (American College of Radiology) 11.
• Long‑axis measurement helps assess nodal burden and stage progression (N1 vs. N2 vs. N3) (American College of Radiology) 12.

Imaging Modality Recommendations

• Contrast‑enhanced CT of the abdomen/pelvis is the reference standard, providing 73 %–97 % diagnostic accuracy and 81 %–100 % specificity (American College of Radiology) 11.
• Intravenous contrast is essential to separate lymph nodes from adjacent vessels and bowel; oral contrast adds further anatomic clarification (American College of Radiology) 13.
• Diffusion‑weighted MRI offers accuracy comparable to CT without the need for gadolinium, making it preferable for younger patients to avoid radiation exposure (American College of Radiology) 13.
• Ultrasound should not be used as the primary imaging modality because it is markedly less accurate and reproducible than CT or MRI (American College of Radiology) 13.

Staging and Additional Imaging

• Chest CT is required to evaluate for thoracic lymphadenopathy and pulmonary metastases (American College of Radiology) 11.
• FDG‑PET/CT may be slightly more sensitive than CT for initial staging but has a higher false‑positive rate; it is not routinely recommended for surveillance of testicular cancer (American College of Radiology) 12.

Limitations and Pitfalls

• Both CT and MRI may miss metastatic disease in normal‑sized nodes; size criteria alone cannot reliably differentiate inflammatory from malignant nodes (American College of Radiology) 12.
• Relying solely on imaging size thresholds is unsafe because inflammatory nodes can mimic malignancy (American College of Radiology) 11.
• Chest radiography alone is insufficient for staging, as it misses the majority of thoracic metastases (American College of Radiology) 13.